The Ministry of Health, Labor and Welfare (MHLW) on November 29 proposed a more stringent application of the current 40% entry price rule for first oral generics towards the FY2024 drug pricing reform.Under the current rule, first oral generics are…
HOME > BUSINESS
BUSINESS
- Ono Sales Down 0.3% Despite New Product Sales Increase, Double-Digit Decline in Profits Due to Higher Cost to Sales Ratio
May 14, 2013
- Takeda Not to Release 3-Year Mid-Term Business Plan, Changes to Annual Business Forecast
May 14, 2013
- Eisai Operating Profit Down 26%, Fails to Meet Revised Domestic Sales Target for Aricpet
May 14, 2013
- Daiichi Sankyo FY2012 Sales Up 6.3%; Leads Way with Near Double-Digit Growth in Japan Pharma Biz
May 14, 2013
- Four Leading Wholesalers See Clear Recovery in Pharmaceutical Wholesale Business
May 14, 2013
- DSP to Increase Latuda Sales Force to 450 in North America
May 13, 2013
- Yakult Pharmaceutical Sales and Profit Down as Elplat Sales Decline
May 13, 2013
- Millennium: Anna Protopapas Becomes President, R&D Functions Integrated into Takeda
May 13, 2013
- Ethical Drug Sales Down 0.7%, OTC Drug Sales Surge 8.9% in March: Crecon Report
May 13, 2013
- Meiji Seika Pharma Leads in Percentage of Female MRs with a Ratio of 1 Female to 3 MRs: Jiho Survey
May 13, 2013
- MTPC Royalties Reach 19.5 Billion Yen from Out-Licensed Gilenya
May 10, 2013
- Shionogi Chalks Up Record Profits as US Unit Buoys Sales
May 10, 2013
- DSP Sales Down 0.8% Due to Long-Listed Product Sales Decline, Double-Digit Growth in Profits
May 10, 2013
- Takeda Sees Sales Rise on Expanding Europe, Emerging Market Biz in FY2012, Yet Operating Profit Sags 50%
May 10, 2013
- No Prospects of Reaching Agreement on Delivery Prices with Wholesalers Even after the Fiscal Year End: Pres. Tajiri of Medical System Network
May 10, 2013
- Eisai to Launch the Obesity Treatment Belviq in the US in June
May 10, 2013
- Ono, DSP to Expand Business for Limaprost in China
May 10, 2013
- Santen’s FY2012 Operating Profit Sinks 7% as Eylea Launch Drives Up Cost Ratio
May 9, 2013
- Astellas Partners with Drais Pharmaceuticals to Develop Nocturia Treatment
May 9, 2013
- MTPC Annual Sales Up 3% with Gilenya Royalities, Remicade Growth
May 9, 2013
ページ
Referrals can be an absolute game-changer in recruitment.When someone in your network recommends a candidate, they often have firsthand insight into the person’s skills, work ethic, values and ambitions. This insider knowledge results in higher quality candidates who are a…
Chugai Pharmaceutical’s Phesgo (pertuzumab + trastuzumab + vorhyaluronidase alfa) and Novartis’ Leqvio (inclisiran) will be newly added to the Japanese reimbursement list along with a batch of other medicines on November 22. Three drugs carry peak sales outlooks of over…
The main players in the FY2024 reimbursement policy reform are now all in place, with the roster rounded out by the appointment of former health minister Katsunobu Kato for the Liberal Democratic Party’s (LDP) prominent social security post at the…
A member of the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry on November 13…
A health ministry study group on pharmaceutical regulations on October 13 roughly agreed on a reform plan for Japanese regulatory…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…